相关实验视频

Updated: Sep 11, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

IGF2BP3作为肺腺癌的新型预后生物标志物和治疗标

Feiming Hu¹, Chenchen Hu¹, Yuanli He^1,2

¹Department of Immunology, Air Force Medical University, No. 169, Changle West Road, Xi'an 710032, China.

|August 13, 2025

概括

胰岛素样生长因子2 mRNA结合蛋白3 (IGF2BP3) 在肺腺癌 (LUAD) 中表达高,推动瘤生长和转移. 向IGF2BP3可能会改善LUAD患者的免疫治疗和精准医学结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

RNA结合蛋白 (RBPs) 在癌症中至关重要,但它们在肺腺癌 (LUAD) 中的作用尚不清楚.
胰岛素样生长因子2和mRNA结合蛋白3 (IGF2BP3) 是一个关键的RBP,在LUAD中具有很大程度上尚未探索的功能.

研究的目的:

研究IGF2BP3在肺腺癌中的临床意义和功能作用.
探索IGF2BP3对瘤进展,免疫逃避以及其作为治疗点的潜力的影响.

主要方法:

单细胞/RNA测序,qPCR,西斑和免疫组织化学被用于分析IGF2BP3表达.
进行了功能测试 (敲击),基因组丰富分析 (GSEA) 和TIDE分析.
分子对接被用于药物查.

主要成果:

在LUAD中,IGF2BP3的调节显著上升,与晚期,转移和不良预后相关.
通过IGF2BP3的淘汰,抑制了增殖,诱导了细胞循环停止和细胞亡.
高IGF2BP3表达与免疫逃避有关,这表明低表达患者的免疫治疗反应更好.

结论:

IGF2BP3是LUAD进展的关键驱动因素,也是预后的潜在生物标志物.
IGF2BP3代表了LUAD免疫疗法和精密医学的一个有前途的治疗标.
BI-2536显示出作为针对低IGF2BP3表达的LUAD的向治疗的潜力.

关键词:

在 IGF2BP3BP3 中.肺部腺癌的癌症.预后生物标志物预后生物标志物治疗目标是治疗的目标.瘤免疫微环境是一个微环境.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...